Kura Sushi to Reproduce Representative Dishes of 70 Countries and Regions Participating in the Osaka-Kansai Expo!
12.12.2024 02:00:00 CET | Business Wire | Press release
70 Expo Special Menu Items UnveiledAntibacterial Sushi Covers with Expo-specific Designs Also Available
Kura Sushi Inc. (Headquarters: Sakai City, Osaka Prefecture), one of the world’s most popular conveyor-belt sushi chains, announced on December 12 that it will offer 70 new menu items at its restaurant that will open at the “Osaka-Kansai Expo,” which will open on April 13 next year in Yumeshima, Osaka, featuring dishes representing 70 countries and regions scheduled to participate in the Expo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211605079/en/
Antibacterial Sushi Covers with Expo-specific Designs (Photo: Business Wire)
The company is the only major revolving sushi chain in Japan to serve sushi on conveyor belts at all of its restaurants. Under the concept of “Revolving Belts Unite the World,” the company will open a restaurant at the Osaka-Kansai Expo with 338 seats, the most in the company’s history, and a revolving belt about 135 meters long, the longest in the company’s history.
With the intention to bring smiles to the faces of visitors from all over the world and provide them with an enjoyable dining experience, the “Hands・Hands Project,” a project that will offer a special 70 Expo menu representing each country and region scheduled to participate in the Expo, will be launched. The menu has been developed by the company’s product development team. The company’s product development team have been working on these menu items with a focus on reproducing the authentic flavors of the countries and regions. Twenty-four of the items have been recreated after being tasted and advised on by ambassadors and other people from these countries under the collaboration with each embassy.
In addition, the antibacterial sushi cover “Mr. Freshness,” which is being used for this special menu, has been specially designed with the connecting part appearing as red and blue hands shaking, the signature colors of the Expo. By serving the special menu side by side with the company’s popular sushi menu, sushi and dishes from different countries and regions flow hand in hand in front of the customers. Along with enjoying their meal, guests will be able to enjoy the experience as if they were visiting a pavilion that explores the culinary cultures of countries around the world.
To help building momentum for the Expo, special Expo menus will be offered ahead of time at about 550 restaurants nationwide, starting on February 7, 2025 (Friday). Each store will offer one item from a menu of 70 different items, as if each store were a “mini-pavilion” where visitors can enjoy the flavors of the respective country. As every neighborhood store will offer a different menu item from a different country or region, customers will be able to enjoy the menu at their local Kura Sushi restaurants, or they can enjoy all 70 items on the Expo special menu by visiting different Kura Sushi restaurants in Japan.
Kaitenzushi (Revolving Sushi Restaurant) is said to have spread throughout Japan after attracting attention at the Osaka Expo in 1970. Since then, Kaitenzushi has steadily expanded its market size while evolving in various ways over its 50-year history, and is now a leading business category in the evolution of the Japanese food service industry, with sales exceeding 800 billion yen. Going forward, the company will continue to leverage its strength, the revolving belt, to provide customers in Japan and overseas with the memorable enjoyment that only Kura Sushi can offer, thereby expanding the revolving sushi business model, a wonderful business model that originated in Japan, to the entire world.
Mr. Makoto Tanaka, Executive Vice President of Kura Sushi, held a press conference on the day of the event, and mentioned, “These days, the world is filled with a variety of social issues that are difficult to solve. Even under such circumstances, we hope that the conveyor-belt sushi restaurants, which are connected by a “conveyor belt that has no beginning and no end,” will unite people from all over the world who visit the Expo to have an enjoyable dining experience with a smile on their faces. We hope that visitors from all over the world, including Japanese customers, as well as tourists from all over the world, will enjoy the menu which we have created with the combined efforts of our Product Development Division to recreate the authentic flavors of the world.”
As of the end of November, Kura Sushi Inc. operates 547 restaurants in Japan, 70 in the United States, 59 in Taiwan, and 3 in Shanghai.
Check out our other products here. https://www.kurasushi.co.jp/2025expo/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211605079/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom